In a study published in «Advanced Materials», researchers Pietro Veglianese, Valeria Veneruso and Emilia Petillo from Istituto di Ricerche Farmacologiche Mario Negri IRCCS in collaboration with Filippo Rossi of the Department of Chemistry, Materials and Chemical Engineering "Giulio Natta" have demonstrated that an innovative nanovector (nanogel), which they developed, is able to deliver anti-inflammatory drugs in a targeted manner into glial cells actively involved in the evolution of spinal cord injury, a condition that leads to paraplegia or quadriplegia.

Treatments currently available to modulate the inflammatory response mediated by the component that controls the brain's internal environment after acute spinal cord injury showed limited efficacy. This is also due to the lack of a therapeutic approach that can selectively act on microglial and astrocytic cells.

The nanovectors developed by Politecnico di Milano, called nanogels, consist of polymers that can bind to specific target molecules. In this case, the nanogels were designed to bind to glial cells, which are crucial in the inflammatory response following acute spinal cord injury. The collaboration between Istituto di Ricerche Farmacologiche Mario Negri IRCCS and Politecnico di Milano showed that nanogels, loaded with a drug with anti-inflammatory action (rolipram), were able to convert glial cells from a damaging to a protective state, actively contributing to the recovery of injured tissue. Nanogels showed to have a selective effect on glial cells, releasing the drug in a targeted manner, maximising its effect and reducing possible side effects.

«The key to the research was understanding the functional groups that can selectively target nanogels within specific cell populations. This makes it possible to optimise drug treatments by reducing unwanted effects», explains Filippo Rossi.

«The results of the study show that nanogels reduced inflammation and improved recovery capacity in animal models with spinal cord injury, partially restoring motor function. These results open the way to new therapeutic possibilities for myelolysis patients. Moreover, this approach may also be beneficial for treating neurodegenerative diseases such as Alzheimer's, in which inflammation and glial cells play a significant role», continues Pietro Veglianese.

> Press release (in Italian) 
> Watch the video | Filippo Rossi, verso nuovi trattamenti per la lesione al midollo spinale con i nanogel (in Italian)

Synergistic Pharmacological Therapy to Modulate Glial Cells in Spinal Cord Injury

Valeria Veneruso, Emilia Petillo, Fabio Pizzetti, Alessandro Orro, Davide Comolli, Massimiliano De Paola, Antonietta Verrillo, Arianna Baggiolini, Simona Votano, Franca Castiglione, Mattia Sponchioni, Gianluigi Forloni, Filippo Rossi, Pietro Veglianese

> View the paper

Release

Nanomedicina e somministrazione di farmaci: innovazioni nella ricerca
Trendsanita.it - 14 Febbraio 2024

Nanomedicine paves the way for new treatments for spinal cord injury
Bioengineer.org - 14 Febbraio 2024

La nanomedicina apre la strada a nuovi trattamenti per la lesione al midollo spinale
Aboutpharma.com - 14 Febbraio 2024

Nanomedicina, nuovi trattamenti per la lesione al midollo spinale
Ecodibergamo.it - 14 Febbraio 2024

La nanomedicina per le lesioni del midollo spinale
ItaliaSalute - 15 Febbraio 2024

Nanomedicine paves the way for new treatments for spinal cord injury
Newswise | Medicine  - 15 Febbraio 2024